rcs research tirzepatide Tirzepatide 20mg Research Peptide-mvanhaasteren.nl Tirzepatide Dual Agonist (GLP-1/GIP) |

In recent years, GLP-1 role in neuronal pathways has expanded its therapeutic potential

A Phase 3 trial shows that oral semaglutide 25 mg achieved up to 16.6% weight loss over 64 weeks in adults with obesity

Monthly dosing, oral delivery, and multi-pathway mechanisms are reshaping the patient journey and the strategic playbook

2.8% [4.7]

Learn what clinical studies reveal about tirzepatide and sexual health, including how weight loss itself influences desire and when to talk to your doctor.

evaluate the translational evidence supporting GLP-1RAs as candidate disease-modifying therapies for neurodegenerative diseases in this installment to the JCIs Review